benzonidazole has been researched along with EHS Tumor in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Maddison, K; Siemann, DW; Wolf, K | 1 |
| Morrissey, S; Siemann, DW; Wolf, K | 1 |
| Twentyman, PR; Workman, P | 1 |
| Workman, P | 1 |
4 other study(ies) available for benzonidazole and EHS Tumor
| Article | Year |
|---|---|
Potentiation of melphalan activity in the KHT sarcoma by the radiosensitizer RSU 1069.
Topics: Animals; Aziridines; Azirines; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Female; Melphalan; Mice; Misonidazole; Neoplasm Transplantation; Nitroimidazoles; Radiation-Sensitizing Agents; Sarcoma, Experimental; Time Factors | 1984 |
In vivo potentiation of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea by the radiation sensitizer benznidazole.
Topics: Animals; Dose-Response Relationship, Drug; Drug Synergism; Lomustine; Mice; Mice, Inbred C3H; Misonidazole; Nitroimidazoles; Nitrosourea Compounds; Radiation-Sensitizing Agents; Sarcoma, Experimental; Time Factors | 1983 |
Chemosensitization by lipophilic nitroimidazoles.
Topics: Animals; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Leukocyte Count; Lomustine; Male; Melphalan; Mice; Mice, Inbred C3H; Misonidazole; Nitroimidazoles; Sarcoma, Experimental; Time Factors | 1983 |
Chemosensitization of lomustine by misonidazole, benznidazole, and RSU 1069.
Topics: Animals; Lomustine; Mice; Mice, Inbred C3H; Misonidazole; Nitroimidazoles; Sarcoma, Experimental | 1986 |